SEARCH

SEARCH BY CITATION

References

  • Adler M., Schulz S., Fischer R. and Niemeyer C. M. (2005) Detection of Rotavirus from stool samples using a standardized immuno-PCR (“Imperacer”) method with end-point and real-time detection. Biochem. Biophys. Res. Commun. 333, 12891294.
  • American Psychiatric Association (Ed.) (2000) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) Washington, DC: APA.
  • Arai H., Morikawa Y., Higuchi M. et al. (1997) Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem. Biophys. Res. Commun. 236, 262264.
  • Blennow K., Wallin A., Agren H., Spenger C., Siegfried J. and Vanmechelen E. (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26(23), 1245.
  • Blennow K., Hampel H., Weiner M. and Zetterberg H. (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131144.
  • Borroni B., Gardoni F., Parnetti L. et al. (2009) Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol. Aging 30, 3440.
  • Compta Y., Parkkinen L., O'Sullivan S. S. et al. (2011) Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 134, 14931505.
  • Dickson D. W., Bergeron C., Chin S. S. et al. (2002) Office of rare diseases neuropathologic criteria for corticobasal degeneration. J. Neuropathol. Exp. Neurol. 61, 935946.
  • Emre M., Aarsland D., Brown R. et al. (2007) Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov. Disord. 22, 16891707.
  • Fagan A. M., Mintun M. A., Mach R.H. et al. (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 59, 512519.
  • Folstein M. F., Folstein S. E. and McHugh P. R. (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189198.
  • Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., Ringheim A., Långström B. and Nordberg A. (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29, 14561465.
  • Goedert M., Spillantini M. G., Jakes R., Rutherford D. and Crowther R. A. (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519526.
  • Hampel H., Blennow K., Shaw L. M., Hoessler Y.C., Zetterberg H. and Trojanowski J. Q. (2010) Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp. Gerontol. 45, 3040.
  • Horowitz P. M., LaPointe N., Guillozet-Bongaarts A. L., Berry R. W. and Binder L. I. (2006) N-terminal fragments of tau inhibit full-length tau polymerization in vitro. Biochemistry 45, 1285912866.
  • Hughes A. J., Daniel S. E., Kilford L. and Lees A. J. (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181184.
  • Hughes A. J., Daniel S. E., Ben-Shlomo Y. and Lees A. J. (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125, 861870.
  • Hutton M., Lendon C. L., Rizzu P. et al. (1998) Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 393, 702705.
  • Jeganathan S., von Bergen M., Brutlach H., Steinhoff H. J. and Mandelkow E. (2006) Global hairpin folding of tau in solution. Biochemistry 45, 22832293.
  • Josephs K. A. and Dickson D. W. (2003) Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov. Disord. 18, 10181026.
  • Kovacech B. and Novak M. (2010) Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease. Curr. Alzheimer Res. 7, 708716.
  • Lill C. M., Roehr J. T., McQueen M. B. et al. (2012) Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet. 8, e1002548.
  • Ling H., O'Sullivan S. S., Holton J. L., Revesz T., Massey L. A., Williams D. R., Paviour D. C. and Lees A. J. (2010) Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 133, 20452057.
  • Litvan I., Hauw J. J., Bartko J. J. et al. (1996) Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J. Neuropathol. Exp. Neurol. 55, 97105.
  • Litvan I., Grimes D. A. and Lang A. E. (2000) Phenotypes and prognosis: clinicopathologic studies of corticobasal degeneration. Adv. Neurol. 82, 183196.
  • Luk C., Giovannoni G., Williams D. R., Lees A. J. and de Silva R. (2009) Development of a sensitive ELISA for quantification of three- and four-repeat tau isoforms in tauopathies. J. Neurosci. Methods 180, 3442.
  • Luk C., Vandrovcova J., Malzer E., Lees A. and de Silva R. (2010) Brain tau isoform mRNA and protein correlation in PSP brain. Translational Neuroscience 1, 3036.
  • Myers A. J., Pittman A. M., Zhao A. S. et al. (2007) The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol. Dis. 25, 561570.
  • Ono K., Noguchi-Shinohara M., Yoshita M., Naiki H. and Yamada M. (2007) Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances alpha-synuclein fibril formation in vitro. Exp. Neurol. 203, 579583.
  • Patterson K. R., Remmers C., Fu Y. et al. (2011) Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J. Biol. Chem. 286, 2306323076.
  • Pittman A. M., Myers A. J., Abou-Sleiman P. et al. (2005) Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J. Med. Genet. 42, 837846.
  • Sano T., Smith C. L. and Cantor C. R. (1992) Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates. Science 258, 120122.
  • de Silva R., Lashley T., Gibb G. et al. (2003) Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol. Appl. Neurobiol. 29, 288302.
  • Sjögren M., Davidsson P., Tullberg M. et al. (2001) Both total and phosphorylated tau are increased in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 70, 624630.
  • Slemmon J. R., Meredith J., Guss V., Andreasson U., Andreasen N., Zetterberg H. and Blennow K. (2012) Measurement of Abeta1-42 in cerebrospinal fluid is influenced by matrix effects. J. Neurochem. 120, 325333.
  • Spillantini M. G., Murrell J. R., Goedert M., Farlow M. R., Klug A. and Ghetti B. (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl Acad. Sci. USA 95, 77377741.
  • Strozyk D., Blennow K., White L. R. and Launer L. J (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652656.
  • Tapiola T., Alafuzoff I., Herukka S. K., Parkkinen L., Hartikainen P., Soininen H. and Pirttilä T. (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 66, 382389.
  • Teunissen C. E., Petzold A., Bennett J. L. et al. (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73, 19141922.
  • Togo T., Sahara N., Yen S. H., Cookson N., Ishizawa T., Hutton M., de Silva R., Lees A. and Dickson D. W. (2002) Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J. Neuropathol. Exp. Neurol. 61, 547556.
  • Tokuda T., Salem S. A., Allsop D., Mizuno T., Nakagawa M., Qureshi M. M., Locascio J. J., Schlossmacher M. G. and El-Agnaf O. M. (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162166.
  • Urakami K., Wada K., Arai H. et al. (2001) Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J. Neurol. Sci. 183, 9598.
  • Vandrovcova J., Anaya F., Kay V., Lees A., Hardy J. and de Silva R. (2010) Disentangling the role of the tau gene locus in sporadic tauopathies. Curr. Alzheimer Res. 7, 726734.
  • Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van Der Perre B., Sjögren M., Andreasen N. and Blennow K. (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 285, 4952.
  • Williams D. R., de Silva R., Paviour D. C., Pittman A., Watt H. C., Kilford L., Holton J. L., Revesz T. and Lees A. J. (2005) Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 128, 12471258.
  • Wray S., Saxton M., Anderton B. H. and Hanger D. P. (2008) Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats. J. Neurochem. 105, 23432352.